Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

108.23 +6.09 (+5.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
65 66 Next >
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
BNTX ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against BioNTech SE (BNTX)
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - January 20, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of... 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
P/E Ratio Insights for BioNTech
Via Benzinga
Comparative Study: BioNTech And Industry Competitors In Biotechnology Industry
Via Benzinga
How Is The Market Feeling About BioNTech?
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of BioNTech SE (BNTX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Understanding BioNTech's Position In Biotechnology Industry Compared To Competitors
Via Benzinga
BioNTech SE (BNTX) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Filed Against BioNTech SE
From Robbins LLP
Via Business Wire
BIONTECH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BIONTECH SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options
From Faruqi & Faruqi LLP
Via GlobeNewswire
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. 
Via Benzinga
BIONTECH SE SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioNTech SE (NASDAQ: BNTX)
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BNTX
From The Rosen Law Firm, P.A.
Via Business Wire
BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... 
Via Talk Markets
BioNTech Prepares To Be Commercial Ready By 2025, Revenue Growth Expected To Return In 2025
On Tuesday, BioNTech SE (NASDAQ: BNTX) outlined priorities at the Annual J.P. 
Via Benzinga
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)... 
Via Talk Markets
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.  
Via Benzinga
Exposures Product Safety
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
From BioNTech SE
Via GlobeNewswire
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n 
Via Benzinga
Exposures COVID-19
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
From BioNTech SE
Via GlobeNewswire
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
Analysts think these beaten-down stocks could rebound strongly in the new year. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.